Walleye Trading’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,200
| Closed | -$113K | – | 4436 |
|
|
2026
Q1 | $113K | Sell |
5,200
-56,000
| -92% | -$1.08M | ﹤0.01% | 3410 |
|
|
2025
Q4 | $1.32M | Buy |
61,200
+24,200
| +65% | +$510K | ﹤0.01% | 2181 |
|
|
2025
Q3 | $713K | Sell |
37,000
-13,800
| -27% | -$246K | ﹤0.01% | 2492 |
|
|
2025
Q2 | $869K | Buy |
+50,800
| New | +$2.17M | ﹤0.01% | 2299 |
|
|
2025
Q1 | – | Sell |
-6,000
| Closed | -$730K | – | 4683 |
|
|
2024
Q4 | $730K | Buy |
6,000
+2,600
| +76% | +$319K | ﹤0.01% | 2362 |
|
|
2024
Q3 | $425K | Sell |
3,400
-40,600
| -92% | -$5.61M | ﹤0.01% | 2617 |
|
|
2024
Q2 | $6.95M | Buy |
44,000
+27,000
| +159% | +$3.47M | 0.02% | 875 |
|
|
2024
Q1 | $2.2M | Sell |
17,000
-8,200
| -33% | -$1M | ﹤0.01% | 1679 |
|
|
2023
Q4 | $2.43M | Sell |
25,200
-22,700
| -47% | -$2.18M | 0.01% | 1779 |
|
|
2023
Q3 | $5.81M | Buy |
47,900
+9,500
| +25% | +$1.07M | 0.02% | 1013 |
|
|
2023
Q2 | $4.4M | Sell |
38,400
-112,800
| -75% | -$14.5M | 0.01% | 1048 |
|
|
2023
Q1 | $20.8M | Buy |
151,200
+68,200
| +82% | +$8.85M | 0.05% | 369 |
|
|
2022
Q4 | $10.8M | Sell |
83,000
-2,600
| -3% | -$301K | 0.03% | 624 |
|
|
2022
Q3 | $9.46M | Buy |
+85,600
| New | +$8.63M | 0.03% | 652 |
|
|
2022
Q1 | – | Sell |
-1,400
| Closed | -$126K | – | 5893 |
|
|
2021
Q4 | $126K | Sell |
1,400
-10,100
| -88% | -$863K | ﹤0.01% | 4257 |
|
|
2021
Q3 | $1.06M | Sell |
11,500
-13,300
| -54% | -$1.02M | ﹤0.01% | 2139 |
|
|
2021
Q2 | $1.93M | Buy |
24,800
+18,900
| +320% | +$1.43M | 0.01% | 1532 |
|
|
2021
Q1 | $440K | Buy |
5,900
+5,800
| +5,800% | +$535K | ﹤0.01% | 2796 |
|
|
2020
Q4 | $17K | Sell |
100
-2,200
| -96% | -$326K | ﹤0.01% | 4399 |
|
|
2020
Q3 | $323K | Buy |
2,300
+100
| +5% | +$15.2K | ﹤0.01% | 2614 |
|
|
2020
Q2 | $353K | Sell |
2,200
-19,600
| -90% | -$2.67M | ﹤0.01% | 2578 |
|
|
2020
Q1 | $2.13M | Buy |
21,800
+20,000
| +1,111% | +$2.29M | 0.02% | 790 |
|
|
2019
Q4 | $232K | Buy |
1,800
+1,300
| +260% | +$131K | ﹤0.01% | 3052 |
|
|
2019
Q3 | $38K | Buy |
+500
| New | +$59K | ﹤0.01% | 3645 |
|
|
2019
Q2 | – | Sell |
-2,100
| Closed | -$250K | – | 4468 |
|
|
2019
Q1 | $250K | Sell |
2,100
-300
| -13% | -$38.6K | ﹤0.01% | 2863 |
|
|
2018
Q4 | $262K | Sell |
2,400
-700
| -23% | -$87.5K | ﹤0.01% | 3107 |
|
|
2018
Q3 | $501K | Buy |
3,100
+2,700
| +675% | +$369K | ﹤0.01% | 2898 |
|
|
2018
Q2 | $53K | Buy |
+400
| New | +$37.7K | ﹤0.01% | 4236 |
|
Other funds holding SRPT
EAM
Walleye Trading's SRPT Position: Q2 2026 in Review
Walleye Trading sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 3,259 shares — an estimated $70.9K sold.
Walleye Trading first reported a position in SRPT in Q2 2016 and held it in 22 quarters. The position peaked at $3.8M in Q4 2023. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Walleye Trading reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
- Walleye Trading sold 3,259 Sarepta Therapeutics shares in Q2 2026, an estimated $70.9K.
- Walleye Trading first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 22 quarters.
- Walleye Trading's Sarepta Therapeutics position peaked at $3.8M in Q4 2023.
- 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.